|Day Low/High||48.15 / 49.06|
|52 Wk Low/High||44.30 / 65.89|
Newmont Mining will acquire Goldcorp in a $10 billion deal, and here's how I'd trade Newmont.
My stated reason for being in Pfizer all along has been price stability and income.
This is the kind of reversal that happens in a bull market.
The RMPIA index was up for the year, while the S&P 500, DJIA, Russell 2000 and Nasdaq all finished 2018 in the red.
NEW ORLEANS, Jan. 8, 2019 /PRNewswire/ -- Former Attorney General of Louisiana Charles C.
It's probably no surprise that my picks for 2019 come from the biotech/biopharma space.
Could there be more M&A this year than Wall Street had thought? Also, GE's quest for more liquidity took another baby step Monday.
Tesla, the big pharma mergers and General Electric are some of the top stories on TheStreet.
Luxoft is to be bought for about $2 billion by DXC Technology.
The Dow Jones Industrial Average is higher Monday amid improved prospects for a trade deal between the U.S. and China.
The company expects revenue to jump 12% year over year.
Are you ready for the week? Action Alerts Plus's Zev Fima breaks down what the portfolio is watching.
Eli Lilly & Co. says Monday it will pay $8 billion in cash for cancer drug specialists Loxo Oncology in the second major pharmaceutical sector deal of the year.
It's likely that investors will be closely watching the U.S.-China trade talks to see if the skies brighten longer term.
Global stocks traded higher Monday, following on from Friday's spectacular rally on Wall Street, as investors cheered much stronger-than-expected U.S. jobs data paired with twin dovish messages from the Federal Reserve and the People's Bank of China that look to support beaten-down asset prices heading into the fourth quarter earnings season.
Pharma companies that have cash are looking at what has happened to this stock market and buying.
Bristol-Myers Squibb Company (NYSE: BMY) today announced that Giovanni Caforio, M.
Jim Cramer says a trade deal could help, but what matters after today is earnings -- and how bad the shortfalls will be.
Bristol-Myers, Apple and the economy are some of the top stories on TheStreet.
All three major indices dropped more than 2% Thursday.
Bristol-Myers Squibb agrees to buy Celgene in a deal that values the cancer drug specialist at $74 billion.
And it is happening not a moment too soon.
It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.
Jim discusses Thursday's market selloff, what Apple's preannouncement means for the stock long term, the announced Bristol-Myers Squibb acquisition of Celgene and how it relates to Amgen, the oil market, and much more!
Jim Cramer's thoughts on Bristol-Myers and how it sets the stage for mergers and acquisitions going into 2019.
Big pharma could be primed for an M&A Boom after Bristol-Myers Squibb's blockbuster deal for Celgene.
BMY agreed to acquire CELG for $74 billion in cash and stock.
Jim Cramer's thoughts on the Bristol-Myers deal and Apple's issues with China.
The big problem this market faces technically is that there isn't much support down to the lows hit on Dec. 24.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.